LB941 KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma
Cernova J, Eskin-Schwartz M, Atzmony L, Samuelov L, De Brito M, Chan J, Aviezer D, Brener E, Lederman R, Mashriki T, Michel D, Barak S, Braiman L, Sprecher E, O’Toole E. LB941 KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma. Journal Of Investigative Dermatology 2024, 144: s164. DOI: 10.1016/j.jid.2024.06.1114.Peer-Reviewed Original ResearchPhase 1b clinical study